225. Congenital nephrogenic diabetes insipidus Clinical trials / Disease details


Clinical trials : 15 Drugs : 48 - (DrugBank : 18) / Drug target genes : 31 - Drug target pathways : 65

  
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05044611
(ClinicalTrials.gov)
January 11, 202327/8/2021AMIloride for the Treatment of Nephrogenic Diabetes Insipidus for Patients With Bipolar Disorder Treated With LithiumAMIloride for the Treatment of Nephrogenic Diabetes Insipidus for Patients With Bipolar Disorder Treated With Lithium: a Randomized Controlled TrialBipolar DisorderDrug: Anhydrous Amiloride Hydrochloride;Drug: PlaceboAssistance Publique - Hôpitaux de ParisNULLRecruiting18 Years70 YearsAll148Phase 4France
2NCT05190744
(ClinicalTrials.gov)
September 1, 202229/12/2021PB to Treat Hereditary Nephrogenic Diabetes Insipidus, ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium AdministrationA Multi-center, Open-Label, Exploratory Study to Assess the Efficacy of PB in Decreasing the Urine Output and Increasing the Urine Osmolality in Patients With Hereditary Nephrogenic Diabetes Insipidus, Patients With Autosomal Dominant Polycystic Kidney Disease Treated With Tolvaptan, And Severely Polyuric Patients With Previous Lithium Administration (Serendipity-PB1)Autosomal Dominant Polycystic Kidney Disease;Nephrogenic Diabetes Insipidus;Acquired Nephrogenic Diabetes Insipidus;Congenital Nephrogenic Diabetes InsipidusDrug: PBMayo ClinicHopital du Sacre-Coeur de MontrealRecruiting18 YearsN/AAll20Phase 2United States
3NCT04939753
(ClinicalTrials.gov)
May 26, 202127/4/2021Nephrogenic Diabetes Insipidus During Prolonged Sevoflurane Sedation in the ICU: a Retrospective AnalysisIncidence of Nephrogenic Diabetes Insipidus During Prolonged Sevoflurane Sedation in the Intensive Care Unit: a Retrospective AnalysisNephrogenic Diabetes InsipidusDrug: SevofluraneUniversitair Ziekenhuis BrusselNULLRecruiting18 YearsN/AAll1000Belgium
4EUCTR2020-002204-38-DK
(EUCTR)
24/11/202007/05/2020Treatment of the genetic disease nephrogenic diabetes insipidus with the antifungal drug FluconazoleTreatment of congenital nephrogenic diabetes insipidus with fluconazole, an antifungal medication Nephrogenic diabetes insipidus
MedDRA version: 21.0;Level: LLT;Classification code 10012600;Term: Diabetes insipidus nephrogenic;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
INN or Proposed INN: Fluconazole
Other descriptive name: FLUCONAZOLE
Claus BistrupNULLAuthorised-recruitment may be ongoing or finishedFemale: no
Male: yes
10Phase 2Denmark
5JPRN-jRCTs031180369
12/04/201818/03/2019Tolvaptan for nephrogenic diabetes insipidusExploratory study of tolvaptan use for nephrogenic diabetes insipidus caused by mutation in vasopressin type 2 receptor - Tolvaptan use for NDI by V2R mutation Nephrogenic diabetes insipidus
Nephrogenic diabetes insipidus, polyuria;D018500
Starting tolvaptan from 60 mg and dose up to 90mg and 120mg in every 1 or 2 days.Makita NorikoNULLRecruiting>= 20age oldNot applicableBoth3Phase 1-2Japan
6EUCTR2016-001591-30-DK
(EUCTR)
06/11/201709/03/2017 Treatment of congenital nephrogenic diabetes insipidus with riociguat or sildenafil Treatment of congenital nephrogenic diabetes insipidus with a guanylate cyclase stimulator, riociguat or a phosphodiesterase type 5 inhibitor, sildenafil Nephrogenic diabetes insipidus because of AVP2R-mutation
MedDRA version: 20.0;Level: LLT;Classification code 10012626;Term: Diabetes nephrogenic (excludes glycosuria);System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Trade Name: Adempas
Product Name: Adempas
INN or Proposed INN: RIOCIGUAT
Other descriptive name: RIOCIGUAT
Trade Name: Viagra
Product Name: Viagra
INN or Proposed INN: SILDENAFIL
Odense University HospitalNULLNot Recruiting Female: no
Male: yes
2 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noDenmark
7NCT02967653
(ClinicalTrials.gov)
July 13, 201715/11/2016Atorvastatin for the Treatment of Lithium-Induced Nephrogenic Diabetes InsipidusAtorvastatin for the Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus: A Randomized Controlled TrialLithium Use, Nephrogenic Diabetes InsipidusDrug: AtorvastatinLady Davis InstituteNULLCompleted18 Years85 YearsAll60Phase 2Canada
8JPRN-UMIN000021708
2016/04/1818/04/2016A study to evaluate effect and safety of Tolvaptan in Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene.A study to evaluate effect and safety of Tolvaptan in Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene. - A study to evaluate effect and safety of Tolvaptan in Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene. Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene1) Administration of Tolvaptan once per day (60mg/day, 90mg/day, 120mg/day), each dose for two days.
2) Administration of Tolvaptan 120mg per day for 2 to 4 weeks in outpatient.
Department of Nephrology and Endocrinology, The University of Tokyo HospitalNULLRecruiting20years-oldNot applicableMale and Female3Not selectedJapan
9NCT02460354
(ClinicalTrials.gov)
September 201529/5/2015Metformin and Congenital Nephrogenic Diabetes InsipidusUse of Metformin to Treat Patients With Congenital Nephrogenic Diabetes Insipidus (NDI)Diabetes InsipidusDrug: MetforminEmory UniversityNULLTerminated18 YearsN/AMale2Phase 1United States
10EUCTR2012-001809-24-NL
(EUCTR)
31/07/201306/09/2012A diminished concentrating ability of the kidneys due to lithium prescription: how many and whom is affected?Evaluation of urinary concentrating defects in lithium treated patients with a dDAVP test - Nephrogenic diabetes insipidus (NDI) in lithium treated patients lithium-induced urinary concentrating defects (nephrogenic diabetes insipidus)
MedDRA version: 15.0;Level: LLT;Classification code 10050501;Term: Lithium toxicity;System Organ Class: 10022117 - Injury, poisoning and procedural complications
MedDRA version: 15.0;Classification code 10012600;Term: Diabetes insipidus nephrogenic;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Trade Name: Desmopressine nasal spray 10 mg/ml, flacon 60 doses
Product Name: Desmopressine nasal spray 10 mg/ml, flacon 60 doses
Product Code: SUB21605
INN or Proposed INN: desmopressin acetate trihydrate
Other descriptive name: DESMOPRESSIN ACETATE TRIHYDRATE
Radboud University Nijmegen Medical CentreNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Netherlands
11EUCTR2011-005970-41-NL
(EUCTR)
27/02/201208/02/2012The effect of the drug acetazolamide on excessive urine production due to a diminished concentrating ability of the kidney as a result of the use of lithium in patients with an affective disorder: a pilot studyThe effect of acetazolamide on lithium-induced nephrogenic diabetes insipidus in patients with an affective disorder: a pilot study lithium-induced nephrogenic diabetes insipidus
MedDRA version: 14.1;Level: LLT;Classification code 10012600;Term: Diabetes insipidus nephrogenic;System Organ Class: 10038359 - Renal and urinary disorders
MedDRA version: 14.1;Classification code 10050501;Term: Lithium toxicity;System Organ Class: 10022117 - Injury, poisoning and procedural complications;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Trade Name: Acetazolamide Sandoz 250
Other descriptive name: ACETAZOLAMIDE
Radboud University Nijmegen Medical CentreNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Netherlands
12EUCTR2006-003360-56-DK
(EUCTR)
28/08/200907/07/2009Farmakologisk behandling af CNDI – Et ”proof-of-concept” studie. - NDI-POC-STUDYFarmakologisk behandling af CNDI – Et ”proof-of-concept” studie. - NDI-POC-STUDY Kongenit nefrogen diabetes insipidus
MedDRA version: 14.1;Level: PT;Classification code 10068304;Term: Congenital nephrogenic diabetes insipidus;System Organ Class: 10010331 - Congenital, familial and genetic disorders
Trade Name: Confortid
INN or Proposed INN: INDOMETACIN
Trade Name: Losec
INN or Proposed INN: OMEPRAZOLE MAGNESIUM
Trade Name: Viagra
Other descriptive name: SILDENAFIL CITRATE
Trade Name: Miacalcic
Other descriptive name: CALCITONIN (SALMON)
Trade Name: Spirix
Other descriptive name: SPIRONOLACTONE
Trade Name: Esidrix
Product Name: Esidrix
INN or Proposed INN: HYDROCHLOROTHIAZIDE
Dept. of Pediatrics, The Childrens Hospital, DenverNULLNot RecruitingFemale: no
Male: yes
40Denmark
13NCT00478335
(ClinicalTrials.gov)
May 200723/5/2007Pharmacologic Treatment of Congenital Nephrogenic Diabetes InsipidusPharmacologic Treatment of Congenital Nephrogenic Diabetes InsipidusNephrogenic Diabetes InsipidusDrug: sildenafil;Drug: calcitonin;Drug: hydrochlorothiazide/amiloride;Drug: indomethacin;Drug: Placebo for sildenafil;Drug: placebo for calcitoninUniversity of Colorado, DenverUniversity of AarhusCompleted5 Years25 YearsMale4N/AUnited States;Denmark
14EUCTR2006-001202-84-NL
(EUCTR)
01/02/200731/01/2007Comparison of the action of amiloride and thiazide in the reduction of lithium-NDI in patients with affective disorders - Treatment lithium-NDI Comparison of the action of amiloride and thiazide in the reduction of lithium-NDI in patients with affective disorders - Treatment lithium-NDI Lithium-induced Nephrogenic Diabetes Insipidus
MedDRA version: 9.1;Level: LLT;Classification code 10012600;Term: Diabetes insipidus nephrogenic
Trade Name: Midamor
Product Name: Amiloride
Trade Name: Hydrochloorthiazide
Product Name: hydrochloorthiazide
Radboud University Nijmegen Medical CentreNULLNot RecruitingFemale: yes
Male: yes
50Phase 4Netherlands
15NCT00004360
(ClinicalTrials.gov)
September 199518/10/1999Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes InsipidusDiabetes Insipidus, NephrogenicDrug: chlorothiazideNational Center for Research Resources (NCRR)Northwestern UniversityCompleted6 Months70 YearsBothN/ANULL